OnabotulinumtoxinA Injection of Sphenopalatine Ganglion May Not Improve Trigeminal Neuralgia
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Onabotulinumtoxin A
Decreased Response to Botulinum Toxin Type A Agents Observed Over Time
Preliminary findings showed the decrease in botulinum toxin type A therapeutic effect over time warrants further study.
Long-Term OnabotulinumtoxinA Safe, Effective for Chronic Migraine Prophylaxis
Long-term use of onabotulinumtoxinA for chronic migraine prophylaxis was associated with reduced headache day frequency and improved quality of life.
Is Botulinum Toxin Effective for Chronic Tension-Type Headache?
Although the quality of evidence is low due to variable study designs, botulinum toxin may be beneficial in the treatment of chronic tension-type headaches for specific patients with clear treatment goals.
Botulinum Toxin Type A Superior to Placebo for Reducing Migraine Frequency
Improvement in quality of life at 3 months was higher in the botulinum toxin group vs the placebo group.
OnabotulinumtoxinA Wearing off Common in Chronic Migraine Prophylaxis
A wearing off of responses to onabotulinumtoxinA during the first treatment cycle may be common in individuals with chronic migraine.
OnabotulinumtoxinA May Reduce Headache Days in Chronic Migraine With Daily Headaches
OnabotulinumtoxinA treatment was found to reduce the frequency of headache days in patients with chronic migraine with and without daily headaches.
OnabotulinumtoxinA Effective in Reducing Depression and Anxiety Symptoms in Chronic Migraines
OnabotulinumtoxinA not only reduced headache frequency for patients with chronic migraines, but also showed potential for clinically reducing depression and anxiety symptoms.
OnabotulinumtoxinA Improves Outcomes in Chronic Migraine With or Without Allodynia
OnabotulinumtoxinA treatment was found to reduce the frequency and severity of monthly headache days and to improve quality of life and disability in patients with chronic migraine with or without allodynia.
OnabotulinumtoxinA May Be Effective for Chronic Migraine With Medication Overuse
OnabotulinumtoxinA at 195 UI may be effective in reducing the number of headaches per month and medication intake in patients with chronic migraine and medication overuse.
Next post in Migraine & Headache
